A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.
A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening All Administered by Inhalation Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasilien, 40110-160
- GSK Investigational Site
-
-
-
-
-
Pleven, Bulgarien, 5800
- GSK Investigational Site
-
Sofia, Bulgarien, 1606
- GSK Investigational Site
-
Sofia, Bulgarien, 1431/1000
- GSK Investigational Site
-
Sofia, Bulgarien, 1619
- GSK Investigational Site
-
Varna, Bulgarien, 9010
- GSK Investigational Site
-
-
-
-
Región Metro De Santiago
-
Santiago, Región Metro De Santiago, Chile, 7500551
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile, 7500691
- GSK Investigational Site
-
-
-
-
-
Kazan, Den Russiske Føderation, 420015
- GSK Investigational Site
-
Moscow, Den Russiske Føderation, 115446
- GSK Investigational Site
-
Moscow, Den Russiske Føderation, 115478
- GSK Investigational Site
-
Moscow, Den Russiske Føderation, 123 182
- GSK Investigational Site
-
St. Petersburg, Den Russiske Føderation, 197022
- GSK Investigational Site
-
St. Petersburg, Den Russiske Føderation, 197 089
- GSK Investigational Site
-
Tomsk, Den Russiske Føderation, 634 050
- GSK Investigational Site
-
Volgograd, Den Russiske Føderation, 400130
- GSK Investigational Site
-
-
-
-
-
Kohtal-Jdrve, Estland, 31 025
- GSK Investigational Site
-
Parnu, Estland, 80024
- GSK Investigational Site
-
Tallinn, Estland, 1162
- GSK Investigational Site
-
Tartu, Estland, 51014
- GSK Investigational Site
-
-
-
-
-
Athens, Grækenland, 115 28
- GSK Investigational Site
-
Athens, Grækenland, 15669
- GSK Investigational Site
-
Papagos/Athens, Grækenland, 15669
- GSK Investigational Site
-
-
-
-
Campania
-
Eboli (SA), Campania, Italien, 84025
- GSK Investigational Site
-
Napoli, Campania, Italien, 80131
- GSK Investigational Site
-
Salerno, Campania, Italien, 84126
- GSK Investigational Site
-
-
Emilia-Romagna
-
Ferrara, Emilia-Romagna, Italien, 44100
- GSK Investigational Site
-
-
Liguria
-
Genova, Liguria, Italien, 16132
- GSK Investigational Site
-
-
Lombardia
-
Sesto San Giovanni (MI), Lombardia, Italien, 20099
- GSK Investigational Site
-
-
Marche
-
Torrette (AN), Marche, Italien, 60126
- GSK Investigational Site
-
-
Toscana
-
Firenze, Toscana, Italien, 50134
- GSK Investigational Site
-
Pisa, Toscana, Italien, 56124
- GSK Investigational Site
-
-
Veneto
-
Bussolengo (VR), Veneto, Italien, 37012
- GSK Investigational Site
-
Padova, Veneto, Italien, 35128
- GSK Investigational Site
-
-
-
-
-
Osijek, Kroatien, 31000
- GSK Investigational Site
-
Split, Kroatien, 21000
- GSK Investigational Site
-
Zagreb, Kroatien, 10000
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexico, 04530
- GSK Investigational Site
-
Mexico, D.F., Mexico, 06720
- GSK Investigational Site
-
-
-
-
-
Brasov, Rumænien
- GSK Investigational Site
-
Bucharest, Rumænien, 050159
- GSK Investigational Site
-
Bucuresti, Rumænien, 70000
- GSK Investigational Site
-
-
-
-
-
Bloemfontein, Sydafrika, 9300
- GSK Investigational Site
-
Cape Town, Sydafrika, 7500
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13086
- GSK Investigational Site
-
Berlin, Tyskland, 10717
- GSK Investigational Site
-
Berlin, Tyskland, 13597
- GSK Investigational Site
-
Berlin, Tyskland, 10969
- GSK Investigational Site
-
Berlin, Tyskland, 10365
- GSK Investigational Site
-
Berlin, Tyskland, 10585
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Schwetzingen, Baden-Wuerttemberg, Tyskland, 68723
- GSK Investigational Site
-
Weinheim, Baden-Wuerttemberg, Tyskland, 69469
- GSK Investigational Site
-
-
Hessen
-
Eschwege, Hessen, Tyskland, 37269
- GSK Investigational Site
-
Gelnhausen, Hessen, Tyskland, 63571
- GSK Investigational Site
-
Kassel, Hessen, Tyskland, 34117
- GSK Investigational Site
-
-
Niedersachsen
-
Hannover, Niedersachsen, Tyskland, 30159
- GSK Investigational Site
-
Hannover, Niedersachsen, Tyskland, 30167
- GSK Investigational Site
-
Lueneburg, Niedersachsen, Tyskland, 21335
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Guetersloh, Nordrhein-Westfalen, Tyskland, 33330
- GSK Investigational Site
-
-
Sachsen
-
Annaberg, Sachsen, Tyskland, 09456
- GSK Investigational Site
-
Aue, Sachsen, Tyskland, 08280
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Geesthacht, Schleswig-Holstein, Tyskland, 21502
- GSK Investigational Site
-
-
Thueringen
-
Erfurt, Thueringen, Tyskland, 99084
- GSK Investigational Site
-
-
-
-
-
Törökbálint, Ungarn, 2045
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Outpatients aged between 16- 65 years.
- Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods
- Documented clinical history of persistent asthma first diagnosed at least 6 months prior to Visit 1
- Currently receiving inhaled short-acting beta-2 agonists for symptom relief
- A lung function of between 50 to 90% predicted (PEF)
- Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol
Exclusion Criteria:
- History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1
- History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.
- A history of two or more asthma exacerbations requiring treatment with oral corticosteroids or hospitalisation in the 6 months before Visit 1.
- Past or present disease that, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematologic disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis and bronchopulmonary dysplasia).
- Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS (e.g., lactose).
- Undergoing allergen desensitisation therapy.
- Neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements.
- Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
Placebo inhaled twice daily (morning and evening) for 28 days
|
|
Eksperimentel: GW685698X (fluticasone furoate) 100mcg Morning
|
GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
|
|
Eksperimentel: GW685698X (fluticasone furoate) 100mcg Evening
|
GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
|
|
Eksperimentel: GW685698X (fluticasone furoate) 250mcg Evening
|
GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Peak expiratory flow (PEF)
Tidsramme: 28 days
|
Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning compared with GW685698X 100mcg once daily in the evening by inhalation via DISKHALER.
|
28 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Peak expiratory flow (PEF)
Tidsramme: 28 days
|
Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 250mcg once daily compared with GW685698X 100mcg once daily both administered in the evening by inhalation via DISKHALER.
|
28 days
|
|
PEF
Tidsramme: 28 days
|
Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning, 100mcg once daily in the evening, or GW685698X 250mcg once daily in the evening, compared with placebo
|
28 days
|
|
Clinic lung function
Tidsramme: 28 days
|
Change from baseline in pre bronchodilator clinic lung function (forced expiratory volume in 1 second [FEV1] and PEF) after 28 days of treatment with GW685698X 250mcg once daily in the evening compared with GW685698X 100mcg once daily in the evening
|
28 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x.
- Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther. 2012 Aug;34(8):1683-95. doi: 10.1016/j.clinthera.2012.06.024. Epub 2012 Jul 13.
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Sygdomme i immunsystemet
- Lungesygdomme
- Overfølsomhed, Øjeblikkelig
- Bronchiale sygdomme
- Lungesygdomme, obstruktiv
- Respiratorisk overfølsomhed
- Overfølsomhed
- Astma
- Lægemidlers fysiologiske virkninger
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Dermatologiske midler
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Anti-allergiske midler
- Fluticason
- Xhance
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- FFA20001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Studiedata/dokumenter
-
Annoteret sagsbetænkningsformular
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datasætspecifikation
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Formular til informeret samtykke
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk undersøgelsesrapport
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Individuelt deltagerdatasæt
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokol
Informations-id: FFA20001Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .